This project has been flagged by a community member as inappropriate due to reason below.*
Expert Interview
Slingshot members are talking to an expert! The topic is:
A Second Opinion: Discussing the potential of Sisunatovir for the treatment of Respiratory Syncytial Virus (RSV).
Ticker(s): PFEWho's the expert?
Institution: Private Practice
- Pulmonologist who manages treatment for 50 patients with Respiratory Syncytial Virus
- Familiar with the research and phase II studies on Sisunatovir
Interview GoalThe goal of this interview is to discuss the potential of Sisunatovir, an oral fusion inhibitor made to prevent respiratory syncytial virus RSV replication by hindering F-mediated fusion with the host cell being investigated for the treatment of RSV infections, currently in development by ReViral
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
